MD FRCP FRCOphth FHEA DCH DRCOG DO
- Tutor and Senior Research Fellow, Harris Manchester College
Prof. Peter Scanlon has been Clinical Director for the English NHS Diabetic Eye Screening Programme since 2003, and he has, with the support and co-operation of colleagues, moved screening from limited ad hoc delivery of services to systematic quality assured processes for screening, assessment and treatment across all of England to 2.3 million people with diabetes. Dr Scanlon also holds an appointment as a Senior Research Fellow and Medical Tutor at Harris Manchester College, University of Oxford, and as Visiting Professor at the University of Gloucestershire. Dr Scanlon is Lead Author of the textbook ‘Practical Manual of Diabetic Retinopathy Management’ and has written the Diabetic Retinopathy Chapter for the Textbook of Diabetes, 4th Edition (both Wiley Blackwell).
His research interests lie in the Screening, Epidemiology, Assessment and Treatment of Diabetic Retinopathy and he has published extensively in these areas.
Improving the screening of risk factors in diabetic retinopathy.
Scanlon PH., (2022), Expert Rev Endocrinol Metab, 17, 235 - 243
Why Is Continued Vision Loss Still a Problem in Some Patients With Diabetic Retinopathy, Despite Treatment?
Bressler SB. et al, (2022), JAMA Ophthalmol, 140, 308 - 309
Should we still be performing macular laser for non-centre involving diabetic macular oedema? Results from a UK centre.
Scanlon PH. et al, (2022), Eye (Lond), 36, 646 - 648
Aflibercept in clinical practice; visual acuity, injection numbers and adherence to treatment, for diabetic macular oedema in 21 UK hospitals over 3 years.
Talks SJ. et al, (2022), Eye (Lond), 36, 72 - 77
Patients views on a new surveillance pathway involving allied non-medical staff for people with treated diabetic macular oedema and proliferative diabetic retinopathy
Prior L. et al, (2022), Eye (Basingstoke)